SPRINT — Sprint Bioscience AB Balance Sheet
0.000.00%
Last trade - 00:00- SEK236.35m
- SEK109.65m
- SEK167.17m
Annual balance sheet for Sprint Bioscience AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | ARS | ARS | ARS | ARS | PRESS |
| Standards: | IFRS | IFRS | IFRS | IFRS | — |
| Status: | Final | Final | Final | Final | Final |
| Cash | |||||
| Cash and Short Term Investments | 70.6 | 29.5 | 49.9 | 25.1 | 127 |
| Net Total Receivables | 5.29 | 5.39 | 7.94 | 12.2 | 6.17 |
| Total Current Assets | 75.9 | 34.9 | 57.9 | 37.2 | 133 |
| Net Property, Plant And Equipment | 2.99 | 2.37 | 4.38 | 4.72 | 3.74 |
| Long Term Investments | |||||
| Long Term Notes Receivable | |||||
| Other Long Term Assets | |||||
| Total Assets | 79.1 | 37.4 | 62.4 | 42.1 | 137 |
| Accounts Payable | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 8.68 | 9.23 | 34.6 | 32.8 | 17.5 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Liabilities | 8.68 | 9.23 | 34.6 | 32.8 | 17.5 |
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Total Equity | 70.5 | 28.2 | 27.8 | 9.27 | 119 |
| Total Liabilities & Shareholders' Equity | 79.1 | 37.4 | 62.4 | 42.1 | 137 |
| Total Common Shares Outstanding |